Review





Similar Products

anti mouse cd8 monoclonal antibody  (Leinco Technologies)
86
Leinco Technologies anti mouse cd8 monoclonal antibody
Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus <t>anti-CD8</t> antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in <t>CD4/CD8-depleted</t> mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.
Anti Mouse Cd8 Monoclonal Antibody, supplied by Leinco Technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse cd8 monoclonal antibody/product/Leinco Technologies
Average 86 stars, based on 1 article reviews
anti mouse cd8 monoclonal antibody - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
anti cd8  (Bio X Cell)
94
Bio X Cell anti cd8
Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus <t>anti-CD8</t> antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in <t>CD4/CD8-depleted</t> mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.
Anti Cd8, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd8/product/Bio X Cell
Average 94 stars, based on 1 article reviews
anti cd8 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
anti human cd8 monoclonal antibody mab  (Cell Signaling Technology Inc)
86
Cell Signaling Technology Inc anti human cd8 monoclonal antibody mab
Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus <t>anti-CD8</t> antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in <t>CD4/CD8-depleted</t> mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.
Anti Human Cd8 Monoclonal Antibody Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd8 monoclonal antibody mab/product/Cell Signaling Technology Inc
Average 86 stars, based on 1 article reviews
anti human cd8 monoclonal antibody mab - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier
monoclonal antibody against cd8a  (Bio X Cell)
97
Bio X Cell monoclonal antibody against cd8a
Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus <t>anti-CD8</t> antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in <t>CD4/CD8-depleted</t> mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.
Monoclonal Antibody Against Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal antibody against cd8a/product/Bio X Cell
Average 97 stars, based on 1 article reviews
monoclonal antibody against cd8a - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
monoclonal antibodies  (Bio X Cell)
97
Bio X Cell monoclonal antibodies
Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus <t>anti-CD8</t> antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in <t>CD4/CD8-depleted</t> mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.
Monoclonal Antibodies, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal antibodies/product/Bio X Cell
Average 97 stars, based on 1 article reviews
monoclonal antibodies - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
anti cd4 monoclonal antibodies  (Bio X Cell)
97
Bio X Cell anti cd4 monoclonal antibodies
Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus <t>anti-CD8</t> antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in <t>CD4/CD8-depleted</t> mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.
Anti Cd4 Monoclonal Antibodies, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd4 monoclonal antibodies/product/Bio X Cell
Average 97 stars, based on 1 article reviews
anti cd4 monoclonal antibodies - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier
anti mouse cd8 monoclonal antibody  (Selleck Chemicals)
95
Selleck Chemicals anti mouse cd8 monoclonal antibody
Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus <t>anti-CD8</t> antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in <t>CD4/CD8-depleted</t> mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.
Anti Mouse Cd8 Monoclonal Antibody, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse cd8 monoclonal antibody/product/Selleck Chemicals
Average 95 stars, based on 1 article reviews
anti mouse cd8 monoclonal antibody - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
anti cd8a monoclonal antibody  (Bio X Cell)
97
Bio X Cell anti cd8a monoclonal antibody
Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus <t>anti-CD8</t> antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in <t>CD4/CD8-depleted</t> mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.
Anti Cd8a Monoclonal Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd8a monoclonal antibody/product/Bio X Cell
Average 97 stars, based on 1 article reviews
anti cd8a monoclonal antibody - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

Image Search Results


Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus anti-CD8 antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in CD4/CD8-depleted mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.

Journal: Cell & Bioscience

Article Title: Overexpression of ONECUT1 suppresses hepatoblastoma progression via modulating tumor cell growth and tumor microenvironment

doi: 10.1186/s13578-026-01569-0

Figure Lengend Snippet: Depletion of T cells partially inhibits ONECUT1-induced hepatoblastoma regression in YAPS127A/ΔN90-β-catenin mice. A Experimental design. FVB/N mice were hydrodynamically injected with YAPS127A/ΔN90-β-catenin/TRE-ONECUT1 plasmids on Day − 24. On Day − 5, mice received i.p. injections of control IgG or anti-CD4 plus anti-CD8 antibodies (CD4/CD8-Ab). On Day 0, DOX treatment was initiated to induce ONECUT1 expression or regular water as a DOX (−) control, accompanied by the same antibody regimen. Mice were sacrificed on Day 3 after DOX induction or the corresponding time point in DOX (−) groups. Four experimental groups were included: DOX (+) + IgG, DOX (+) + CD4/CD8-Ab, DOX (−) + IgG, and DOX (−) + CD4/CD8-Ab. B , C Quantification of liver weight ( B ) and liver-to-body weight ratio ( C ). Under DOX (+) conditions, T-cell depletion significantly attenuated ONECUT1-induced tumor regression (* P < 0.05). In contrast, under DOX (−) conditions, CD4/CD8 depletion did not significantly affect liver weight or liver-to-body weight ratio. Statistical significance was determined by a two-tailed unpaired Student’s t-test. Data are presented as mean ± SD. ns, not significant; * P < 0.05; *** P < 0.001; **** P < 0.0001. D Representative gross liver morphology and histological analyses. Images from DOX (+) groups are shown. H&E staining (40×) shows larger tumor burden in CD4/CD8-depleted mice. Ki67 immunostaining (200×) indicates higher proliferation in CD4/CD8-Ab–treated livers. CD4 and CD8 immunostaining (200×) confirms successful T-cell depletion.

Article Snippet: To deplete CD4+ and CD8+ T cells in mice, anti-mouse CD4 monoclonal antibody (clone GK1.5, Purified in vivo GOLDTM Functional Grade, Leinco Technologies) and anti-mouse CD8 monoclonal antibody (clone YTS 169, Purified in vivo GOLDTM Functional Grade, Leinco Technologies) were administered.

Techniques: Injection, Control, Expressing, Two Tailed Test, Staining, Immunostaining